Skip to main
ANRO
ANRO logo

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience Inc is making significant strides in developing innovative treatment options for psychiatric disorders, particularly with solid advancements in their clinical-stage assets like ALTO-207 and ALTO-101, which have shown enhanced tolerability and safety profiles compared to existing therapies. The ability of ALTO-207 to achieve higher dosages through a fast titration regimen is expected to improve treatment outcomes for patients suffering from depressive symptoms, thus reinforcing the potential for success in this therapeutic area. Furthermore, the development of new transdermal formulations for ALTO-101 and the promising data from agomelatine studies bolster confidence in the efficacy and safety of Alto's expanding pipeline, leading to enhanced market outlook for its stock.

Bears say

Alto Neuroscience Inc's stock has experienced significant pressure since its IPO in 2024, primarily due to the failure of its lead asset, ALTO-100, in a crucial Phase 2b study for major depressive disorder (MDD) in October 2024, compounded by negative data from ALTO-300. The company still has ongoing clinical trials, including a Phase 2b study in bipolar depression, but these programs are considered high-risk with a low probability of success (POS). Additionally, concerns about the efficacy and safety profile of its product candidates, including common side effects and suboptimal therapeutic outcomes compared to standard treatments, further contribute to a negative outlook.

ANRO has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Buy based on their latest research and market trends.

According to 6 analysts, ANRO has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.